Could Naloxone Improve Survival Rates in Cardiac Arrest Patients?
Surprisingly, naloxone was associated with improved clinical outcomes in both drug-related cardiac arrests and non-drug-related cardiac arrests.
Tag: opioid induced respiratory depression
All
Latest
All
Latest
Faster Naltrexone Protocol Improves Opioid Treatment Success
Starting extended-release naltrexone within five to seven days of seeking treatment improves success rates for opioid addiction compared to the standard 10-15 days, but requires closer medical supervision.
All
Latest
Higher Buprenorphine Doses Improve Treatment Retention for Opioid Use Disorder
Patients prescribed the FDA-recommended dose were significantly more likely to discontinue treatment over 180 days compared to those prescribed a higher dose, an NIH-supported study found.
ED Use of Buprenorphine Safe, Effective for Fentanyl Users
Results from a multi-site clinical trial showed that less than 1% of people with opioid use disorder whose drug use includes fentanyl experienced withdrawal when starting buprenorphine in the emergency department.
Read More
Telehealth, Opioid Use Disorder Meds Reduced Overdose Fatalities
The expanded availability of opioid use disorder-related telehealth services and medications during the COVID-19 pandemic was associated with a lowered likelihood of fatal drug overdose among Medicare beneficiaries.
Read MoreFDA Approves Amphastar’s Naloxone Nasal Spray
The FDA approved Amphastar Pharma’s naloxone hydrochloride nasal spray (4mg) for the emergency treatment of known or suspected opioid overdose.
Read More
NIH Harm Reduction Research Network Targets Opioid Overdose Fatalities
Harm reduction is an evidence-based, often life-saving approach that directly engages people who use drugs to prevent overdose, disease transmission and other harms.
Read More
Electrical Stimulation Restores Breathing in Anesthetized Patients
Administering electrical pulses to the back of the neck of patients undergoing opioid sedation can help patients regain respiratory control following high dosage opioid use, according to new research.
Read More
Electrical Stimulation Treats Opioid-induced Respiratory Depression
A novel treatment for opioid-induced respiratory depression that administers electrical pulses to the back of the neck helped anesthetized patients undergoing neurosurgery regain respiratory control following high dosage opioid use.
Read More
Post-surgical Pediatric Opioid Prescriptions Plummet
Opioid prescriptions for children who underwent one of eight common outpatient surgeries declined over a period of five years, according to research published in Pediatrics.
Read More
FDA Approves Naloxone Auto-Injector for Exposure to Ultra-Potent Weaponized Opioids
Kaleo’s Naloxone Auto-injector 10 mg received FDA approval and is intended for military personnel facing the potential threat of exposure to synthetic opioids on the battlefield.
Read More
FDA Advancing Development of Nonaddictive Opioid Alternatives
The FDA has issued draft guidance to provide recommendations to companies developing non-opioid analgesics for acute pain lasting up to 30 days.
Read More
Teva Generic Narcan Now Available to Treat Opioid Overdoses
Teva says its generic version of the nasal spray Narcan is the first to arrive on the market.
Read More
Kaleo to Pay $12.7M Over False Claim Allegations for Naloxone
Kaléo will pay the United States $12.7 million to resolve allegations that Kaléo caused the submission of false claims for the drug Evzio, an injectable form of naloxone hydrochloride for opioid overdose.
Read More
Opioid Overdose Deaths Increased 38% in Black Americans
A new NIH study found that non-Hispanic Black individuals in four US states experienced a 38% increase in the rate of opioid overdose deaths from 2018 to 2019, while the rates for other race and ethnicity groups held steady or decreased.
Read More